OBJECTIVE: To examine whether vaginal progesterone is non-inferior to 17-hydroxyprogesterone caproate (17-OHPC) in the prevention of preterm birth (PTB) in women with a prior spontaneous PTB. STUDY DESIGN: Women with a singleton gestation and a history of spontaneous PTB who received prenatal care at a single tertiary medical center from 2011-2016 were included in this retrospective cohort. Pregnancies were excluded if they did not initiate progesterone therapy prior to 24 weeks or had a fetus with a major congenital anomaly. PTB <37 weeks was the primary outcome. A priori, the acceptable margin for medical non-inferiority was set to 9% points above the expected PTB<37 rate of 36%, allowing for a 25% relative upper bound on the non-inferiority margin. Adjusted differences in PTB proportions and 90% two-sided confidence intervals were estimated via inverse probability weighted (IPW) regression with adjustment for multiple pregnancies per woman. Secondary outcomes included: PTB <34 and <28 weeks, spontaneous PTB, neonatal intensive care unit (NICU) admission, and gestational age at delivery. RESULTS: Of the 860 pregnancies included, 41% received vaginal progesterone and 59% were given 17-OHPC. Women in the vaginal progesterone group were more likely to be characterized as "other" race/ethnicity, to have had their earliest spontaneous PTB between 32-36 weeks, and to deliver after 2014. The propensity score model adjusted for treatment selection bias and included all covariates included in Table 1 . After adjustment, the proportion of PTB <37 weeks was found to be non-inferior among pregnancies in which vaginal progesterone was used compared to 17-OHPC (37.7% vs. 35.4%; IPW adjusted difference: 2.2%, 90% CI: -4.3, 8.8). IPW adjusted differences for secondary outcomes also fell below the 9% threshold and were therefore also considered to be non-inferior (Table 2) . CONCLUSION: In women with a history of spontaneous PTB, we found vaginal progesterone to be non-inferior to 17-OHPC for the prevention of PTB. While these results await confirmation in a randomized controlled trial, vaginal progesterone may be an effective alternative to 17-OHPC in this population. 
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